Literature DB >> 16397405

Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder.

Aleksandra Szczepankiewicz1, Maria Skibinska, Joanna Hauser, Agnieszka Slopien, Anna Leszczynska-Rodziewicz, Paweł Kapelski, Monika Dmitrzak-Weglarz, Piotr M Czerski, Janusz K Rybakowski.   

Abstract

Glycogen synthase kinase-3beta (GSK-3beta) has been implicated in the pathogenesis of major psychoses. In this paper, the T-50C polymorphism of the GSK-3beta gene has been studied in patients with schizophrenia (n=432), patients with bipolar disorder (n=416) and in a healthy control group (n=408). Consensus diagnosis by at least two psychiatrists was made for each patient, according to DSM-IV and ICD-10 criteria, using the Structured Clinical Interview for DSM-IV Axis I Disorders. Genotypes were established by the polymerase chain reaction-restriction fragment length polymorphism method. We have found a trend towards an association for the C allele in the whole group of schizophrenic patients (p=0.088) and for the heterozygous T/C genotype of bipolar patients (0.095). Significant differences of genotype distribution and allele frequencies of the T-50C polymorphism were found in the female group of bipolar II patients (p=0.015 for genotypes and p=0.009 for alleles). In conclusion, this polymorphism may be associated with female gender in bipolar II disorder. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397405     DOI: 10.1159/000090704

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  21 in total

Review 1.  Clock gene variants in mood and anxiety disorders.

Authors:  Timo Partonen
Journal:  J Neural Transm (Vienna)       Date:  2012-04-27       Impact factor: 3.575

Review 2.  Circadian genes, rhythms and the biology of mood disorders.

Authors:  Colleen A McClung
Journal:  Pharmacol Ther       Date:  2007-02-28       Impact factor: 12.310

3.  An Association Study Between Genetic Polymorphisms in Functional Regions of Five Genes and the Risk of Schizophrenia.

Authors:  Peng Yan; Xiaomeng Qiao; Hua Wu; Fangyuan Yin; Jing Zhang; Yuanyuan Ji; Shuguang Wei; Jianghua Lai
Journal:  J Mol Neurosci       Date:  2016-04-07       Impact factor: 3.444

Review 4.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

5.  Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder.

Authors:  Guodi Chen; Jun Tang; Guangwei Yu; Yiping Chen; Liancong Wang; Yao Zhang
Journal:  Mol Biol Rep       Date:  2014-06-15       Impact factor: 2.316

6.  Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia.

Authors:  Hader A Mansour; Michael E Talkowski; Joel Wood; Kodavali V Chowdari; Lora McClain; Konasale Prasad; Debra Montrose; Andrea Fagiolini; Edward S Friedman; Michael H Allen; Charles L Bowden; Joseph Calabrese; Rif S El-Mallakh; Michael Escamilla; Stephen V Faraone; Mark D Fossey; Laszlo Gyulai; Jennifer M Loftis; Peter Hauser; Terence A Ketter; Lauren B Marangell; David J Miklowitz; Andrew A Nierenberg; Jayendra Patel; Gary S Sachs; Pamela Sklar; Jordan W Smoller; Nan Laird; Matcheri Keshavan; Michael E Thase; David Axelson; Boris Birmaher; David Lewis; Tim Monk; Ellen Frank; David J Kupfer; Bernie Devlin; Vishwajit L Nimgaonkar
Journal:  Bipolar Disord       Date:  2009-11       Impact factor: 6.744

7.  Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance.

Authors:  Siddheshwar J Utge; Pia Soronen; Anu Loukola; Erkki Kronholm; Hanna M Ollila; Sami Pirkola; Tarja Porkka-Heiskanen; Timo Partonen; Tiina Paunio
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

8.  GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.

Authors:  Hui Tang; Na Shen; Huijuan Jin; Dan Liu; Xiaoping Miao; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2013-02-27       Impact factor: 5.590

Review 9.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

Authors:  Michael K Rowe; Charlotte Wiest; De-Maw Chuang
Journal:  Neurosci Biobehav Rev       Date:  2007-03-15       Impact factor: 8.989

10.  Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population.

Authors:  Akiko Okuda; Taro Kishi; Tomo Okochi; Masashi Ikeda; Tsuyoshi Kitajima; Tomoko Tsunoka; Takenori Okumukura; Yasuhisa Fukuo; Yoko Kinoshita; Kunihiro Kawashima; Yoshio Yamanouchi; Toshiya Inada; Norio Ozaki; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2009-09-04       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.